{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Invokana&page=2", "query": { "intervention": "Invokana", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Invokana&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-15T07:50:06.036Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05390892", "title": "PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type2Diabetes", "ASCVD" ], "interventions": [ { "name": "SGLT2 inhibitor", "type": "DRUG" }, { "name": "GLP-1 receptor agonist", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 6000, "start_date": "2022-09-26", "completion_date": "2029-03-01", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-15T07:50:06.036Z", "location_count": 36, "location_summary": "Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 31 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05390892" }, { "nct_id": "NCT01081834", "title": "The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Canagliflozin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 678, "start_date": "2010-03", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2017-02-23", "last_synced_at": "2026-09-15T07:50:06.036Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Concord, California • Greenbrae, California + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Spring Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01081834" }, { "nct_id": "NCT03190798", "title": "Effects of Canagliflozin on Intravascular Volume and Hemodynamics", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type2 Diabetes Mellitus", "Cardiovascular Diseases" ], "interventions": [ { "name": "Canagliflozin 300mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2017-09-01", "completion_date": "2018-08-01", "has_results": false, "last_update_posted_date": "2017-10-12", "last_synced_at": "2026-09-15T07:50:06.036Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03190798" }, { "nct_id": "NCT02324842", "title": "Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Canagliflozin", "type": "DRUG" }, { "name": "Liraglutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 45, "start_date": "2014-11", "completion_date": "2019-03-31", "has_results": true, "last_update_posted_date": "2019-12-18", "last_synced_at": "2026-09-15T07:50:06.036Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02324842" }, { "nct_id": "NCT02920918", "title": "Treatment of Diabetes in Patients With Systolic Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Heart Failure, Systolic", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Canagliflozin", "type": "DRUG" }, { "name": "Sitagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2016-10", "completion_date": "2018-09", "has_results": true, "last_update_posted_date": "2019-10-29", "last_synced_at": "2026-09-15T07:50:06.036Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02920918" }, { "nct_id": "NCT02071368", "title": "A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Canagliflozin, 300 mg", "type": "DRUG" }, { "name": "Metformin XR, 500 mg", "type": "DRUG" }, { "name": "CANA/MET XR FDC, Formulation 1, 150 mg/500", "type": "DRUG" }, { "name": "CANA/MET XR FDC, Formulation 2, 150 mg/500 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 3, "start_date": "2014-02", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-07-01", "last_synced_at": "2026-09-15T07:50:06.036Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02071368" }, { "nct_id": "NCT07547878", "title": "Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Kidney Disease", "Type 2 Diabetes" ], "interventions": [ { "name": "Finerenone", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" }, { "name": "Lotensin", "type": "DRUG" }, { "name": "Capoten", "type": "DRUG" }, { "name": "Enalapril", "type": "DRUG" }, { "name": "Monopril", "type": "DRUG" }, { "name": "Lisinopril", "type": "DRUG" }, { "name": "Univasc", "type": "DRUG" }, { "name": "Aceon", "type": "DRUG" }, { "name": "Accupril", "type": "DRUG" }, { "name": "Altace", "type": "DRUG" }, { "name": "Mavik", "type": "DRUG" }, { "name": "Edarbi", "type": "DRUG" }, { "name": "Atacand", "type": "DRUG" }, { "name": "Avapro", "type": "DRUG" }, { "name": "Cozaar", "type": "DRUG" }, { "name": "Benicar", "type": "DRUG" }, { "name": "Micardis", "type": "DRUG" }, { "name": "Diovan", "type": "DRUG" }, { "name": "Invokana", "type": "DRUG" }, { "name": "Farxiga", "type": "DRUG" }, { "name": "Jardiance", "type": "DRUG" }, { "name": "Ertugliflozin", "type": "DRUG" }, { "name": "Brenzavvy", "type": "DRUG" }, { "name": "Sotagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "84 Years", "sex": "ALL", "summary": "18 Years to 84 Years" }, "enrollment_count": 64, "start_date": "2026-04-30", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-09-15T07:50:06.036Z", "location_count": 1, "location_summary": "Temple, Texas", "locations": [ { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07547878" }, { "nct_id": "NCT01340664", "title": "An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Canagliflozin 50 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Canagliflozin 150 mg", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 279, "start_date": "2011-07", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2014-09-16", "last_synced_at": "2026-09-15T07:50:06.036Z", "location_count": 26, "location_summary": "Little Rock, Arkansas • National City, California • Spring Valley, California + 23 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "National City", "state": "California" }, { "city": "Spring Valley", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Marianna", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01340664" }, { "nct_id": "NCT02597309", "title": "The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes, Obesity" ], "interventions": [ { "name": "Canagliflozin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joslin Diabetes Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2015-11", "completion_date": "2017-07", "has_results": false, "last_update_posted_date": "2017-03-01", "last_synced_at": "2026-09-15T07:50:06.036Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02597309" }, { "nct_id": "NCT01106625", "title": "The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Canagliflozin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Sulphonylruea", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 469, "start_date": "2010-05", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2013-06-20", "last_synced_at": "2026-09-15T07:50:06.036Z", "location_count": 37, "location_summary": "Huntsville, Alabama • Little Rock, Alaska • Phoenix, Arizona + 34 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Little Rock", "state": "Alaska" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Chino", "state": "California" }, { "city": "Fair Oaks", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01106625" } ] }